Citations

Clear

513 citation(s) found for "Ta, Casey".

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Yacoub, Abdulraheem , Borate, Uma , Rampal, Raajit K. , Ali, Haris , Gerds, Aaron T. , Kremyanskaya, Marina , Winton, Elliott F., Goel, Swati , Schiller, Gary J. , McCloskey, James, Palmer, Jeanne , Holmes, Houston, Hager, Steven, Assad, Albert , Erickson‐Viitanen, Susan, Zhou, Feng , Gerds, Aaron T , Goel, Swati , Oh, Stephen T , Palmer, Jeanne M , Daver, Naval , Wang, Eunice S. , Hobbs, Gabriela , O'Connell, Casey Lee , Oh, Stephen T. , Daver, Naval

Mayo Clinic

Blood Advances | January 30, 2024 | Volume: 8 | Issue: 6 | Pages: 1515-1528

10.1182/bloodadvances.2023011620 | PMID 38290135 Get It

Abstract Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.
Mis-spliced transcripts generate de novo proteins in TDP-43–related ALS/FTD
Seddighi, Sahba , Qi, Yue , Brown, Anna‐Leigh , Wilkins, Oscar G. , Bereda, Colleen , Belair, Cédric , Zhang, Yong‐Jie , Prudencio, Mercedes , Keuss, Matthew J. , Khandeshi, Aditya J , Pickles, Sarah , Hill, Sarah E. , Hawrot, James , Ramos, Daniel M. , Roberts, Jessica P. , Sacramento, Erika Kelmer , Shah, Syed Islamuddin , Nalls, Mike A., Colon, J , Reyes, Joel F. , Ryan, Veronica H. , Nelson, Matthew P. , Cook, Casey , Screven, Laurel A. , Kwan, Justin , Mehta, Puja R. , Zanovello, Matteo , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P. , Ahmed, Aisha , Ule, Jernej , Jacobson, Steven , Reich, Daniel S. , Rohrer, Jonathan D. , Malaspina, Andrea , Glass, Jonathan D. , Seyfried, Nicholas T., Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E. , Fratta, Pietro , Qi, Yue A , Khandeshi, Aditya , Yuan, Hebao , Roberts, Jessica , Sacramento, Erika Kelmer , Shah, Syed I , Colón-Mercado, Jennifer M , Reyes, Joel F , Ryan, Veronica H , Cook, Casey N , Li, Ziyi , Screven, Laurel , Mehta, Puja R , Zanovello, Matteo , Hallegger, Martina , Shantaraman, Anantharaman , Ping, Lingyan , Koike, Yuka , Oskarsson, Björn , Staff, Nathan P , Duong, Duc M , Ahmed, Aisha , Secrier, Maria , Ule, Jernej , Jacobson, Steven , Reich, Daniel S , Rohrer, Jonathan D , Dickson, Dennis W , Glass, Jonathan D , Seyfried, Nicholas T , Maragkakis, Manolis , Petrucelli, Leonard , Fratta, Pietro , Ward, Michael E , Zhang, Yong-Jie , Prudencio, Mercedes , Bereda, Colleen , Fratta, Pietro , Li, Ziyi , Dickson, Dennis W. , Ori‬‬, Alessandro , Seyfried, Nicholas T.

Mayo Clinic

Science Translational Medicine | January 26, 2024 | Volume: 16 | Issue: 734 | Pages: No page available

10.1126/scitranslmed.adg7162 | PMID 38277467 Get It

Functional loss of TDP-43, an RNA binding protein genetically and pathologically linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), leads to the inclusion of cryptic exons in hundreds of transcripts during disease. Cryptic exons can promote the degradation of affected transcripts, deleteriously altering cellular function through loss-of-function mechanisms. Here, we show that mRNA transcripts harboring cryptic exons generated de novo proteins in TDP-43–depleted human iPSC–derived neurons in vitro, and de novo peptides were found in cerebrospinal fluid (CSF) samples from patients with ALS or FTD. Using coordinated transcriptomic and proteomic studies of TDP-43–depleted human iPSC–derived neurons, we identified 65 peptides that mapped to 12 cryptic exons. Cryptic exons identified in TDP-43–depleted human iPSC–derived neurons were predictive of cryptic exons expressed in postmortem brain tissue from patients with TDP-43 proteinopathy. These cryptic exons produced transcript variants that generated de novo proteins. We found that the inclusion of cryptic peptide sequences in proteins altered their interactions with other proteins, thereby likely altering their function. Last, we showed that 18 de novo peptides across 13 genes were present in CSF samples from patients with ALS/FTD spectrum disorders. The demonstration of cryptic exon translation suggests new mechanisms for ALS/FTD pathophysiology downstream of TDP-43 dysfunction and may provide a potential strategy to assay TDP-43 function in patient CSF.
TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia
Marks, Jordan D. , Ayuso, Virginia Estades, Carlomagno, Yari , Yue, Mei, Todd, Tiffany W. , Hao, Ying , Li, Ziyi , McEachin, Zachary T. , Shantaraman, Anantharaman , Daughrity, Lillian M. , Jansen‐West, Karen , Calliari, Anna , Bejarano, Jesús González , DeTure, Michael , Rawlinson, Bailey, Castanedes‐Casey, Monica , Lilley, Meredith T. , Donahue, Megan , Jawahar, Vidhya Maheswari, Petersen, Ronald C. , Oskarsson, Björn , Graff‐Radford, Neill R. , Josephs, Keith A. , Seyfried, Nicholas T., Ward, Michael E. , Zhang, Yong‐Jie , Prudencio, Mercedes , Petrucelli, Leonard , Cook, Casey , Duong, Duc M , Daughrity, Lillian M , Jansen-West, Karen R , Shao, Wei , Calliari, Anna , Bejarano, Jesus Gonzalez , DeTure, Michael , Castanedes-Casey, Monica , Lilley, Meredith T , Donahue, Megan H , Boeve, Brad , Petersen, Ronald C , Knopman, David S. , Oskarsson, Björn , Wszolek, Z.K. , Dickson, Dennis W , Josephs, Keith A , Qi, Yue A , Seyfried, Nicholas T , Ward, Michael E , Zhang, Yong-Jie , Prudencio, Mercedes , Petrucelli, Leonard , Cook, Casey N , Li, Ziyi , Shantaraman, Anantharaman , Estades Ayuso, Virginia , Shao, Wei , Bharathi, Vidhya , Boeve, Bradley F. , Knopman, David S. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Qi, Yue , Seyfried, Nicholas T.

Mayo Clinic

Science Translational Medicine | January 17, 2024 | Volume: 16 | Issue: 730 | Pages: No page available

10.1126/scitranslmed.adf9735 | PMID 38232138 Get It

Genetic variation at the transmembrane protein 106B gene ( TMEM106B) has been linked to risk of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) through an unknown mechanism. We found that presence of the TMEM106B rs3173615 protective genotype was associated with longer survival after symptom onset in a postmortem FTLD-TDP cohort, suggesting a slower disease course. The seminal discovery that filaments derived from TMEM106B is a common feature in aging and, across a range of neurodegenerative disorders, suggests that genetic variants in TMEM106B could modulate disease risk and progression through modulating TMEM106B aggregation. To explore this possibility and assess the pathological relevance of TMEM106B accumulation, we generated a new antibody targeting the TMEM106B filament core sequence. Analysis of postmortem samples revealed that the TMEM106B rs3173615 risk allele was associated with higher TMEM106B core accumulation in patients with FTLD-TDP. In contrast, minimal TMEM106B core deposition was detected in carriers of the protective allele. Although the abundance of monomeric full-length TMEM106B was unchanged, carriers of the protective genotype exhibited an increase in dimeric full-length TMEM106B. Increased TMEM106B core deposition was also associated with enhanced TDP-43 dysfunction, and interactome data suggested a role for TMEM106B core filaments in impaired RNA transport, local translation, and endolysosomal function in FTLD-TDP. Overall, these findings suggest that prevention of TMEM106B core accumulation is central to the mechanism by which the TMEM106B protective haplotype reduces disease risk and slows progression.
Clinical value of CSF TMEM106B in familial and sporadic frontotemporal lobar degeneration
Wise, Amy B. , Li, Jingyao , Worringer, Katie, Heuer, Hilary W. , Ljubenkov, Peter A. , Staffaroni, Adam M. , Lago, Argentina Lario , Ramos, Eliana Marisa , Marks, J., Cook, Casey , Pernieel, Jolien, Rademakers, Rosa , Petrucelli, Leonard , Rosen, Howard J. , Boxer, Adam L. , ALLFTD, Rojas, Julio C. , Cobigo, Yann , Loureiro, Joseph , Worringer, Katie, VandeVrede, Lawren , Prudencio, Mercedes , Boeve, Bradley F. , ALLFTD

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S15 | Pages: No page available

10.1002/alz.080210 Get It

AbstractBackgroundTMEM106B, a lysosomal trafficking protein, is an important genetic susceptibility risk factor for frontotemporal lobar degeneration (FTLD). In GRN mutation carriers, minor allele homozygosity in the TMEM106B rs1990622 SNP modulates the risk of FTLD. TMEM106B is often the main component of amyloid fibrils in FTLD with TDP43 aggregates. TMEM106B has been quantified in human brain specimens, but its role as a fluid biomarker is unknown. Here, we investigate the clinical value of CSF TMEM106B in FTLD.MethodsCSF TMEM106B was quantified with SOMAmer proteomics (v3.0, SomaLogic®) in an original cohort of C9orf72, GRN and MAPT symptomatic and asymptomatic mutation carriers and family non‐carrier controls, recruited through ALLFTD (n = 182), and a validation cohort of sporadic neuropathology‐confirmed FTLD‐tau and FTLD‐TDP43, clinically‐diagnosed progressive supranuclear palsy – Richardson syndrome (PSP‐RS) and age‐matched controls (n = 96). CSF TMEM106B was correlated with disease severity, measured by the Frontotemporal Lobar Degeneration module global scores (CDR+NACC/FTLD); brain volume, measured with Bayesian linear mixed‐effect modeling, using age, sex and total‐intracranial volume‐corrected permutations with threshold‐free cluster enhancement; and CSF neurofilament light chain (NfL) measured with Simoa. TMEM106B SOMAmer specificity was validated in cell culture overexpression systems and human brain specimens with high TMEM106B burden.ResultsIn both cohorts, there were no differences in CSF TMEM106B by sex, phenotype or neuropathological diagnosis, except for lower levels in PSP‐RS compared to controls (‐0.31 Log2‐fold change, p < 0.001). CSF TMEM106B did not correlate with age. Regardless of disease‐causing mutation, lower CSF TMEM106B was associated with worse disease severity (Figure 1 and 2). CSF TMEM106B was lower in homozygous TMEM106B rs1990622 protective allelein C9orf2 and MAPT, but not in GRN mutation carriers (Figures 3). CSF TMEM106B showed a trend for inverse correlation with NfL in the whole sample (r = ‐0.135, p = 0.052), and correlated positively with left frontal volume in symptomatic FTLD mutation gene carriers (p < 0.05).ConclusionCSF TMEM106B is quantifiable in CSF in vivo. CSF TMEM106B levels are affected by an interaction of disease severity and FTLD and TMEM106B genotypes. Further work is needed to determine its value as a clinical biomarker.
Uncovering Novel Modifiers of Tau Aggregation and Pathology using a Proximity Proteomics Approach (BioID)
Lee, Jannifer H. , Smith, Courtney L. , Wren, Melissa C. , Tsai, Chih‐Wei , Liu, Feilin , Carlomagno, Yari , DeTure, Michael , Cook, Casey , Golde, Todd E. , Petrucelli, Leonard , Morderer, Dmytro , Khalil, Bilal , Tsai, Chih‐Wei, Croft, Cara L. , Dickson, Dennis W. , Rossoll, Wilfried

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S13 | Pages: No page available

10.1002/alz.079920 Get It

AbstractBackgroundAlzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles (NFTs), comprised primarily of microtubule‐associated protein tau. NFTs are defining hallmarks of AD and its accumulation into pathological oligomers and fibrils has been associated with cognitive decline in AD and other tauopathies. Despite its pivotal role in the disease process, we still have a poor understanding of how their formation, toxicity, and spread across brain regions is regulated via tau‐associated proteins that regulate the oligomerization, pathological accumulation, and seeding of tau in affected cell types and vulnerable brain regions.MethodWe have established two proximity‐dependent biotin‐identification (BioID) models as novel approaches to identify the composition and proximal molecular environment of tau aggregates. Using an in vitro and ex vivo model approach coupled with mass spectrometry, we have identified proteins that were primarily associated with mutant tau aggregates vs. soluble wildtype tau and stratified them based on significance, molecular pathway and druggability. Immunoblotting and immunofluorescence were performed to assess the interaction of endogenous and overexpressed top candidates with tau, along with visualization with NFTs in the context of human AD pathology to assess their impact on tau‐aggregate formation and toxicity.ResultTo determine the physiological and aggregate specific interacting partners of tau, we are comparing wild type tau (TauWT) with mutant tau (Tau3xMUT) carrying three tauopathy‐associated mutations (A152T/P301L/S320F). The proteomic analysis from our combined proteomic datasets revealed that significantly changed proteins included candidates involved in RNA processing, as well as protein ubiquitination and proteasome degradation. We have begun validating proteins that are enriched in mutant tau in human tissue of AD, as well as primary tauopathies, that may be druggable targets for tauopathies.ConclusionThis study provides novel insights into cellular pathways and molecular mechanisms of neurodegeneration, by identifying in the context of living neurons and brain tissue different functional classes of tau‐associated proteins with relevance for AD pathophysiology. These are expected to include proteins that may mediate the toxic effect of NFTs, facilitate the formation or degradation of pathological tau aggregates, and catalyze posttranslational modifications of tau oligomers and associated proteins.
Clinicopathologic features of a novel star-shaped transactive response DNA-binding protein 43 (TDP-43) pathology in the oldest old
Carlos, Arenn F. , Sekiya, Hiroaki , Gatto, Rodolfo G. , Casey, Monica Castanedes, Pham, Nha Trang Thu, Sintini, Irene , Jack, Clifford R. , Lowe, Val J. , Whitwell, Jennifer L. , Petrucelli, Leonard , Reichard, R. Ross , Petersen, Ronald C. , Josephs, Keith A. , Josephs, Keith A , Jack, Clifford R , Whitwell, Jennifer L , Carlos, Arenn F , Sekiya, Hiroaki , Koga, Shunsuke , Machulda, Mary M. , Dickson, Dennis W.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | December 12, 2023 | Volume: 83 | Issue: 1 | Pages: 36-52

10.1093/jnen/nlad105 | PMID 38086178 Get It

Abstract Transactive response DNA-binding protein 43 (TDP-43) pathology is categorized as type A-E in frontotemporal lobar degeneration and as type α-β in Alzheimer disease (AD) based on inclusion type. We screened amygdala slides of 131 cases with varying ages at death, clinical/neuroimaging findings, and AD neuropathologic changes for TDP-43 pathology using anti-phospho-TDP-43 antibodies. Seven cases (5%) only showed atypical TDP-43 inclusions that could not be typed. Immunohistochemistry and immunofluorescence assessed the atypical star-shaped TDP-43 pathology including its distribution, species, cellular localization, and colocalization with tau. All 7 had died at an extremely old age (median: 100 years [IQR: 94–101]) from nonneurological causes and none had dementia (4 cognitively unimpaired, 3 with amnestic mild cognitive impairment). Neuroimaging showed mild medial temporal involvement. Pathologically, the star-shaped TDP-43-positive inclusions were found in medial (subpial) amygdala and, occasionally, in basolateral regions. Hippocampus only showed TDP-43-positive neurites in the fimbria and subiculum while the frontal lobe was free of TDP-43 inclusions. The star-shaped inclusions were better detected with antibodies against N-terminal than C-terminal TDP-43. Double-labeling studies confirmed deposition of TDP-43 within astrocytes and colocalization with tau. We have identified a novel TDP-43 pathology with star-shaped morphology associated with superaging, with a homogeneous clinicopathologic picture, possibly representing a novel, true aging-related TDP-43 pathology.
Smad Ubiquitination Regulatory Factor-2 and Phosphorylated Smad2/3 Immunoreactivity in Pick's Disease (P04.153)
Castanedes‐Casey, Monica , Nakamura, Masataka , Murray, Melissa E. , Dickson, Dennis W.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p04.153 Get It

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems
Garcia‐Manero, Guillermo , McCloskey, James, Yee, Karen , Al‐Kali, Aref , Deeg, H. Joachim , Patel, Prapti A. , Keating, Mary‐Margaret, Zhu, Nancy , Gabrail, Nashat , Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi , Busque, Lambert , Buckstein, Rena , Amin, Harsh, Randhawa, Jasleen K., Lee, Shannon, Chan, Winny, Souza, Sônia Buongermino de, Sano, Yuri, Griffiths, Elizabeth A. , Zeidan, Amer M. , Sabloff, Mitchell , Kantarjian, Hagop M. , Dezern, Amy Elizabeth , O'Connell, Casey Lee , Roboz, Gail J. , Leber, Brian F. , Souza, Sonia, Keer, Harold N , Savona, Michael R.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4619-4619

10.1182/blood-2023-188258 Get It

Background: Oral decitabine/cedazuridine (ASTX727) is a fixed dose combination of decitabine (35 mg) and the cytidine deaminase inhibitor cedazuridine (100 mg) given once daily X 5 days on a 28-day cycle producing pharmacokinetic (PK) exposure equivalent to the standard intravenous (IV) decitabine regimen of 20 mg/m 2 daily X 5 days on a 28-day cycle. This was demonstrated in the pivotal ASCERTAIN study (Garcia-Manero, et al, ASH 2019) as it provided a PK bridge to existing decitabine data and demonstrated median OS was 31.7 mo. (Savona,et al. Intl. MDSF International Congress on MDS, 2021). Subjects were initially classified by the International Prognosis Scoring System (IPSS) for historical reasons, however IPSS-R and IPSS-M are enhancements to IPSS that provide dynamic risk assessment for predicting clinical outcomes in MDS. Here, the objective was to re-classify the MDS subjects enrolled on the ASCERTAIN study by IPSS-R and IPSS-M and measure the impact of informing patient outcomes based on re-calculated risk assessment. Methods: One hundred thirty-three subjects with MDS/CMML (chronic myelomonocytic leukemia) were enrolled in ASCERTAIN and were randomly assigned either IV decitabine for cycle 1 and oral decitabine/cedazuridine for cycle 2 or the opposite treatment sequence. All subjects continuing beyond cycle 2 received oral decitabine/cedazuridine for all subsequent cycles until treatment discontinuation for disease progression, toxicity, patient's decision, or HSCT. Whole blood collected prior to treatment was used for DNA isolation and molecular abnormalities identified using next-generation sequencing (NGS) hematologic malignancy panel of 179 genes including all genes commonly mutated in MDS. In the initial analysis of clinical outcomes, subjects were classified by IPSS with response assessment by IWG 2006 IPSS low and Int-1 risk levels were categorized as lower-risk MDS (LR-MDS), whereas IPSS Int-2 and high-risk categories were categorized as higher-risk MDS (HR-MDS). Subjects with sufficient data based on (e.g., available heme parameters, cytogenetics, NGS etc.) were reclassified by IPSS-R and IPSS-M. Subjects with IPSS-R score of ≤3.5 or IPSS-M of either very low, low, or moderate low were categorized as LR-MDS. Similarly subjects with IPSS-R score of &gt;3.5 or an IPSS-M categorization of either moderate high, high, or very high were categorized as HR-MDS. Reclassified subjects were reassessed for CR (Complete Response), OS, and LFS and Harrell's concordance index (c-index) was used to describe the level of agreement between each scale and outcomes. Results: Based on the available data, the number of MDS subjects in the different risk classifications were the following: IPSS: 117, IPSS-R: 104, and IPSS-M: 105. Thirteen and 12 subjects on the IPSS could not be reclassified in the IPSS-R and IPSS-M, respectively, including 5 Int-1 and 2 low-risk MDS cases. CMML subjects were excluded from these analyses. Re-classification generally resulted in the upgrade of the subjects from LR-MDS to HR-MDS (Fig. 1). Thirty-one (26.5%) subjects from IPSS were reallocated in the IPSS-R to different risk categories; 3 (9.7%) were downgraded and 28 (90.3%) were upgraded. Similarly on reclassification with IPSS-M 34 (32.4%) of the patients reclassified; 5 (14.8%) were downgraded and 29 (85.3%) were upgraded. For IPSS LR-MDS, 23.2% of patients achieved CR, and 22.9% in the IPSS HR-MDS. Similarly, 21.6% patients achieved CR in the IPSS-R LR-MDS, and 23.9% in the IPSS-R HR-MDS; 26.3% patients achieved CR in the IPSS-M LR-MDS, and 20.9% in the IPSS-M HR-MDS. The c-index for the IPSS was .64 (OS) and .67 (LFS), IPSS-R was .70 (OS) and .71 (LFS), and .75 (OS) and .78 (LFS) for the IPSS-M (Table1). Conclusion: Reclassification from IPSS to IPSS-R or IPSS-M upgraded multiple subjects from a LR to a HR category, describing the ASCERTAIN patient population as a majority higher risk population with worse prognosis than previously assumed based on the IPSS. The efficacy as measured by the CR rates did not change when the LR and HR categories were defined by the different risk stratification systems. In contrast, the c-index improves with migration from IPSS to IPSS-R to IPSS-M, indicating an increased discriminatory ability of IPSS-M score in comparison to IPSS and IPSS-R, to predict patient outcomes.
Enabling the clinical application of artificial intelligence in genomics: a perspective of the AMIA Genomics and Translational Bioinformatics Workgroup
Walton, Nephi , Nagarajan, Radha, Wang, Chen , Sincan, Murat , Everman, David B. , Walton, Derek C, Alekseyenko, Alexander V. , Song, Qianqian , Uzun, Ece D. Gamsiz , Taylor, Casey Overby , Uzun, Alper , Person, Thomas N., Benos, Panayiotis V , Alekseyenko, Alexander V , Song, Qianqian , Rappoport, Nadav , Zhao, Zhongming , Wang, Chen , Gamsiz Uzun, Ece D , Nagarajan, Radha , Freimuth, Robert R. , McGrath, Scott , Lemas, Dominick J. , Williams, Marc S

Mayo Clinic

Journal of the American Medical Informatics Association | December 1, 2023 | Volume: 31 | Issue: 2 | Pages: 536-541

10.1093/jamia/ocad211 | PMID 38037121 Get It

Abstract Objective Given the importance AI in genomics and its potential impact on human health, the American Medical Informatics Association—Genomics and Translational Biomedical Informatics (GenTBI) Workgroup developed this assessment of factors that can further enable the clinical application of AI in this space. Process A list of relevant factors was developed through GenTBI workgroup discussions in multiple in-person and online meetings, along with review of pertinent publications. This list was then summarized and reviewed to achieve consensus among the group members. Conclusions Substantial informatics research and development are needed to fully realize the clinical potential of such technologies. The development of larger datasets is crucial to emulating the success AI is achieving in other domains. It is important that AI methods do not exacerbate existing socio-economic, racial, and ethnic disparities. Genomic data standards are critical to effectively scale such technologies across institutions. With so much uncertainty, complexity and novelty in genomics and medicine, and with an evolving regulatory environment, the current focus should be on using these technologies in an interface with clinicians that emphasizes the value each brings to clinical decision-making.